Welcome to our dedicated page for Psyched Wellness news (Ticker: PSYCF), a resource for investors and traders seeking the latest updates and insights on Psyched Wellness stock.
Psyched Wellness Ltd. develops and distributes health and wellness products derived from the Amanita Muscaria mushroom. Company news centers on its consumer supplement portfolio, including Calm, Calmer, AME-1 extract and related dietary supplement formats, along with product formulation, shelf-life, safety-study and flavor-profile updates.
Recurring developments also include retail and wholesale distribution relationships in Canada and the United States, manufacturing and supply-chain matters, regulatory and policy commentary affecting botanical wellness products, and board or executive governance changes. The company’s updates often connect product commercialization with route-to-market partnerships and the regulatory risks associated with Amanita Muscaria-derived consumer products.
Summary not available.
Psyched Wellness Ltd. (CSE:PSYC, OTCQB:PSYCF, FRANKFURT:5U9) is set to present at the KCSA Psychedelics Investor Conference on October 14 at 11:00am E.T. Jeffrey Stevens, CEO, will discuss the company's focus on artisanal functional and psychedelic mushrooms. Psyched aims to lead in the North American market with its Amanita muscaria-derived products targeting stress relief, relaxation, and restful sleep. Interested parties can register for the conference here.